The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials.
Year: 2015
Type: conference-abstract
Study designs: Systematic Review, Meta-Analysis
Source: Journal of Clinical Oncology
Institutions: National Health and Medical Research Council, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Kindai University, Tohoku University Hospital, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Tongji University, Shanghai Pulmonary Hospital, Chiang Mai University, Izumi City General Hospital, Albert Einstein College of Medicine, Jacobi Medical Center, Chinese University of Hong Kong, National Taiwan University, National Taiwan University Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2473066458